FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 19:57:51 25/06/2024 BST | ||
| 1.92 EUR | +1.05% |
|
| Current month | -7.69% | ||
| 1 month | -7.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 1.92 | +1.05% |
| 24/06/24 | 1.9 | -2.56% |
| 21/06/24 | 1.95 | +0.52% |
| 20/06/24 | 1.94 | -1.52% |
| 19/06/24 | 1.97 | +0.51% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 07:57 pm
More quotesStatic data
| Product type | Productos Exóticos |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2P4T |
| ISIN | DE000JK2P4T7 |
| Date issued | 23/02/2024 |
| Strike | 712.4 $ |
| Maturity | Unlimited |
| Parity | 117.84 : 1 |
| Emission price | 2.52 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.94 € |
|---|---|
| Lowest since issue | 1.8 € |
| Spread | 0.04 € |
| Spread % | 2.05% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
